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Dear Editor, 
   In a recently published paper, Tursi et al. have shown that in the period between 1996 and 2006, in 
Central (Lazio region) and Southern (Puglia region) Italy, with a standard clarithromycin-based triple 
therapy, there has been a dramatically significant decrease of Helicobacter pylori (H. pylori) 
eradication rate (from 90% to 51%, respectively, P=0.001).1   
   The Maastricht IV/Florence Consensus Report of the European Helicobacter Study Group have 
advised that a clarithromycin-based triple therapy should be used as first choice in treating H. pylori 
infection, in relation to clarithromycin resistance rate in each region.2 Recently, data of a multicentric 
European study have shown that in Italy the primary rate of H. pylori clarithromycin resistance was 
26.7%.3  
   In 2002, in a randomized study, we have shown that in Turin, Northern Italy, a triple therapy with 
clarithromycin, amoxycillin and a proton pump inhibitor (PPI) achieved a eradication rate of 68% for 7 
days and 76% for 10 days. To continue further gave no advantages.4 These values were significantly 
inferior than those reported 10-year earlier.5 In a series of subsequent studies, we have not found better 
results with alternative schedules.6,7 
   In the year 2012 (January, 01-December, 31) we have prospectively evaluated the H. pylori 
eradication rate of consecutive patients never treated for H. pylori with a clarithromycin-based triple 
therapy comprising a standard dose of PPI twice, amoxycillin 1 g twice daily and clarithromycin 500 
twice a day. Furthermore, results were compared with a previous prospective study, in the same 
geographical region, including patients randomly treated with a triple therapy based on a standard dose 
of PPI, amoxycillin and clarithromycin.4 Eradication of H.pylori infection was assessed by 13C-UBT, 
performed according to the supplier’s instructions (Helicobacter Test, INFAI®, Bochum, Germany). 
The reported sensitivity is 97.9% and specificity 98.5%. Two breath collections were obtained at 
baseline (8 hours of fasting, not PPI nor antibiotics from 30 days) and thirty minutes, respectively, after 
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drink of 100 mg dose of 13C-labeled urea with 1.2 g of citric acid in 100 ml of water. Samples were 
analysed for 13C/12C ratio with a mass spectrometer (BreathMAT plus, Finnigan, Bremen, Germany). 
Results were expressed as excess ð13CO2 excretion per mil, which represents 
13C enrichment over and 
above the baseline sample: a value 4 delta per mil was considered positive. Statistical analyses and 
data processing were performed using the software MedCalc version 12.3. Differences in eradication 
rates were tested with the chi-square test (with Yates’ correction for continuity). A P value <0.05 was 
considered significant. The cohort included 182 patients (81 males, mean age 59.6, range 31-79), 99 of 
them received a regimen including a 1-week triple therapy (group I) and 83 were treated with a 10-day 
triple therapy (group II). No patients treated for different periods were found. Sixty-nine of them had a 
previous diagnosis of peptic ulcer disease or gastrodudenal erosions and the remaining of active 
gastritis. At the end of the course of treatment, the overall H. pylori eradication rate was 70.7% (70/99) 
in group I and 73.4% (61/83) in group II, without significant difference between the 2 regimens. When 
compared with the prospective study published in the year 2002 no differences were observed for both 
groups (P = 0.87 and P = 0.9 respectively))(Figure 1).4  For either duration of therapy, eradication rate 
remains above 70%; since these results represent the “real world”, these are a realistic representation of 
anti-H. pylori treatment in Northwestern Italy. 
    In conclusion, this study has shown that in our area, a clarithromycin-based treatment regimen for H. 
pylori eradication is equally effective than 10 years ago. Nevertheless, in accordance with Tursi et al.,1 
these eradication rates are significantly inferior than those reported 17 years ago.  
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